Multiple myeloma

Assessment combines clonal plasma cells in marrow or a biopsy-proven plasmacytoma with attributable organ injury or a validated myeloma-defining biomarker. CRAB refers to hypercalcemia, renal impairment, anemia and bone lesions attributable to the plasma-cell disorder—not unrelated common abnormalities.

SLiM biomarkers include marrow clonal plasma cells of at least 60%, an involved/uninvolved free-light-chain ratio of at least 100 with the involved level at least 100 mg/L, or more than one MRI focal lesion of at least 5 mm. Interpret borderline or isolated findings with specialist review and the complete diagnostic criteria.

MGUS, smoldering myeloma and solitary plasmacytoma are different clinical settings. Protein studies, free light chains, marrow tests and appropriate whole-body imaging help avoid treating the wrong category. Nonsecretory disease may require greater reliance on marrow and imaging.

Observation remains important for lower-risk smoldering disease. For high-risk SMM, the US FDA now approves subcutaneous daratumumab/hyaluronidase monotherapy based on AQUILA. Confirm that active myeloma has been excluded and that the patient matches the intended risk group; this indication does not cover other SMM risk categories.

Discuss the estimated progression risk, monitoring alternative, treatment duration, infection burden and personal priorities. A risk label from one trial is not automatically identical to every contemporary risk calculator.

Marrow FISH and molecular findings, albumin, beta-2 microglobulin, LDH and imaging contribute to risk assessment. R2-ISS and other contemporary models refine prognosis. Extramedullary disease, circulating plasma cells and an unexpectedly early relapse can add risk not captured by a single baseline score.

The team also assesses frailty, mobility, neuropathy, cardiac and kidney function, infection history, caregiver support and treatment logistics. Transplant suitability is a clinical assessment, not an age cutoff alone.

For suitable transplant candidates, induction commonly combines an anti-CD38 antibody with a proteasome inhibitor, an immunomodulatory drug and dexamethasone. Daratumumab–VRd has a US indication for induction and consolidation in transplant-eligible newly diagnosed disease. Stem cells are collected before high-dose therapy and autologous rescue; the transplant is part of a treatment sequence, not a stand-alone cure.

For transplant-ineligible adults, daratumumab–VRd gained a US indication following CEPHEUS. Less-intensive combinations or adjusted schedules remain important for frailty, neuropathy or organ impairment. A four-drug regimen should not be assumed to be best for every older patient.

Maintenance aims to extend disease control after initial therapy. Lenalidomide is a common foundation, with additional or alternative agents considered according to risk, the original regimen, tolerability and local guidance. Ask which component is intended to continue and how toxicity will be managed.

MRD testing can detect disease below conventional response thresholds, but interpretation depends on assay sensitivity, marrow quality, imaging and sustained results. MRD-guided stopping studies are promising; a single negative test is not a general instruction to stop maintenance or skip transplant.

At each relapse, review which drugs the disease is refractory to, how long previous control lasted, organ injury, cytogenetic evolution and whether progression is biochemical or symptomatic. Remaining active combinations may involve proteasome inhibitors, immunomodulatory agents, anti-CD38 antibodies or newer mechanisms. Early referral preserves cellular-therapy and trial options.

Iberdomide with daratumumab/hyaluronidase and dexamethasone received US accelerated approval after at least one prior line including a proteasome inhibitor and an immunomodulatory agent. The supporting MRD-negative complete-response endpoint is not the same as proven survival improvement; the trial excluded resistance to prior anti-CD38 therapy or bortezomib.

Belantamab mafodotin is an antibody–drug conjugate, not CAR-T. Its current US combination with bortezomib/dexamethasone is for at least two prior lines including those drug classes. Corneal toxicity and vision changes require a structured eye-monitoring and dose-management program.

CAR-T requires collection and manufacturing of a patient’s T cells, with bridging treatment when needed. Cilta-cel’s US indication includes adults after at least one prior line containing a proteasome inhibitor and an immunomodulatory agent who are lenalidomide-refractory. Other products have different line and exposure requirements.

Bispecific antibodies recruit existing T cells without personalized manufacturing. Teclistamab plus daratumumab/hyaluronidase now has a US indication after at least one prior line including a proteasome inhibitor and an immunomodulatory agent; its later-line monotherapy indication has traditional approval. These are distinct regimens and eligibility rules.

Linvoseltamab is a BCMA-directed bispecific; talquetamab targets GPRC5D. Their US monotherapy indications require at least four prior lines including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. Prior BCMA treatment, infection risk, disease speed and target choice shape sequencing; cross-trial response rates cannot select a winner.

CAR-T and T-cell engagers require planning for cytokine-release syndrome, neurological toxicity, low blood counts and serious infections. Step-up dosing, observation, local accommodation, caregiver support and an emergency contact plan are treatment requirements rather than optional conveniences.

Longer-term monitoring matters. Cilta-cel labeling includes immune effector cell-associated enterocolitis and secondary malignancy concerns; persistent diarrhea or abdominal symptoms need assessment. Talquetamab may affect taste, oral intake, skin and nails. Infection prevention and immunoglobulin support are individualized.

Myeloma-related kidney injury can require urgent disease control and coordinated renal care. Free-light-chain reduction, medication review and careful fluid management matter; dialysis may be needed for standard indications, but mechanical protein-removal procedures do not replace effective antimyeloma therapy.

Bone protection, dental assessment, pain control and fracture or spinal-stability review accompany systemic treatment. New severe back pain with weakness, numbness or bladder/bowel dysfunction needs emergency assessment for cord compression. Fever, reduced urine output, confusion or severe dehydration also need prompt care.

Bring marrow and FISH reports, protein/light-chain trends, imaging, kidney function, every regimen with dates and best response, maintenance exposure and reasons for stopping. Ask which therapies remain active, whether a cellular-treatment referral should happen now, and what local approval, manufacturing time and infection support mean for access.